


PHARMACEUTICAL 2019

KalVista Pharmaceuticals Inc. Rank 206 of 363









KalVista Pharmaceuticals Inc. Rank 206 of 363



The relative strengths and weaknesses of KalVista Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KalVista Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of KalVista Pharmaceuticals Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 67%, being 30% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 59,380 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 23,216 |
| Liabilities, Non-Current | 10,920 |
| Other Assets | 173 |
| Other Compr. Net Income | 1,534 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 2,900 |
| Other Revenues | 8,394 |
| Property and Equipment | 1,836 |
| Research and Development | 18,237 |
| Selling, General and Administrative Expense | 8,862 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 61,389 |
| Liabilities | 34,136 |
| Expenses | 27,099 |
| Revenues | 8,394 |
| Stockholders Equity | 27,253 |
| Net Income | -15,805 |
| Comprehensive Net Income | -15,038 |
| Economic Capital Ratio | 67% |

